The Journal of Pediatrics
Volume 152, Issue 4 , Pages 527-533.e1 , April 2008

The Placebo Response in Studies of Acute Migraine

  • Ricardo Fernandes, MD

      Affiliations

    • Pediatrics Department, Santa Maria Hospital, Lisbon, Portugal
    • Corresponding Author InformationCorrespondence: Ricardo Fernandes, Biblioteca de Pediatria, Clínica Universitária de Pediatria, Faculdade de Medicina de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal.
    • ,
  • Joaquim J. Ferreira, MD

      Affiliations

    • Neurological Clinical Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal.
    • ,
  • Cristina Sampaio, MD, PhD

      Affiliations

    • Neurological Clinical Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal.

Received 3 May 2007 ,Revised 26 June 2007 ,Accepted 11 September 2007.

References 

  1. Abu-Arefeh I, Russell G. Prevalence of headache and migraine in schoolchildren. BMJ. 1994;309:765–769
  2. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8:1–96
  3. Headache Classification Subcomittee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia. 2004;24:9–160
  4. Raieli V, Raimondo D, Gangitano M, D’Amelio M, Cammalleri R, Camarda R. The IHS classification criteria for migraine headaches in adolescents need minor modifications. Headache. 1996;36:362–366
  5. Hershey AD, Winner P, Kabbouche MA, Gladstein J, Yonker M, Lewis D, et al. Use of the ICHD-II criteria in the diagnosis of pediatric migraine. Headache. 2005;45:1288–1297
  6. Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology. 2004;63:2215–2224
  7. Damen L, Bruijn JK, Verhagen AP, Berger MY, Passchier J, Koes BW. Symptomatic treatment of migraine in children: a systematic review of medication trials. Pediatrics. 2005;116:e295–e302
  8. European Medicines Agency. Assessment of pediatric needs: migraine. http://www.emea.europa.eu/pdfs/human/peg/22451506en.pdfAccessed February 2007
  9. Rothner AD, Wasiewski W, Winner P, Lewis D, Stankowski J. Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. Headache. 2006;46:101–109
  10. Lewis DW, Winner P, Wasiewski W. The placebo responder rate in children and adolescents. Headache. 2005;45:232–239
  11. Loder E, Goldstein R, Biondi D. Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls. Cephalalgia. 2005;25:124–131
  12. World Medical Association. Policy Statement (Declaration of Helsinki: Ethical Principals For Research Involving Human Subjects). Ferney-Voltaire, France: World Medical Association; 2004;
  13. Caldwell PH, Butow PN, Craig JC. Pediatricians’ attitudes toward randomized controlled trials involving children. J Pediatr. 2002;141:798–803
  14. Caldwell PH, Butow PN, Craig JC. Parents’ attitudes to children’s participation in randomized controlled trials. J Pediatr. 2003;142:554–559
  15. Caldwell PH, Murphy SB, Butow PN, Craig JC. Clinical trials in children. Lancet. 2004;364:803–811
  16. Macedo A, Farre M, Banos JE. A meta-analysis of the placebo response in acute migraine and how this response may be influenced by some of the characteristics of clinical trials. Eur J Clin Pharmacol. 2006;62:161–172
  17. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? (An analysis of clinical trials comparing placebo with no treatment). N Engl J Med. 2001;344:1594–1602
  18. de la Fuente-Fernandez R, Schulzer M, Stoessl AJ. The placebo effect in neurological disorders. Lancet Neurol. 2002;1:85–91
  19. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol. 2002;31:150–153
  20. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996;17:1–12
  21. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ. 2003;327:557–560
  22. Winner P, Prensky A, Linder S, DeBussey S, Asgharnejad M. Adolescent migraine: efficacy and safety of sumatriptan tablets. J Neurol Sci. 1997;150:S17–S22
  23. Rothner AD, Edwards K, Kerr L, DeBussey S, Asgharnejad M. Efficacy and safety of naratriptan tablets in adolescent migraine. J Neurol Sci. 1997;150:S106
  24. Kellstein DE, Lipton RB, Geetha R, Koronkiewicz K, Evans FT, Stewart WF, et al. Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study. Cephalalgia. 2000;20:233–243
  25. Hamalainen ML, Hoppu K, Valkeila E, Santavuori P. Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology. 1997;48:103–107
  26. Hamalainen ML, Hoppu K, Santavuori PR. Oral dihydroergotamine for therapy-resistant migraine attacks in children. Pediatr Neurol. 1997;16:114–117
  27. Hamalainen ML, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study (Do children with migraine respond to oral sumatriptan differently from adults?). Neurology. 1997;48:1100–1103
  28. Ueberall MA, Wenzel D. Intranasal sumatriptan for the acute treatment of migraine in children. Neurology. 1999;52:1507–1510
  29. Winner P, Rothner AD, Saper J, Nett R, Asgharnejad M, Laurenza A, et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics. 2000;106:989–997
  30. Winner P, Lewis D, Visser WH, Jiang K, Ahrens S, Evans JK. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache. 2002;42:49–55
  31. Lewis DW, Kellstein D, Dahl G, Burke B, Frank LM, Toor S, et al. Children’s ibuprofen suspension for the acute treatment of pediatric migraine. Headache. 2002;2:780–786
  32. Visser WH, Winner P, Strohmaier K, Klipfel M, Peng Y, McCarroll K, et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. Headache. 2004;44:891–899
  33. Ahonen K, Hamalainen ML, Rantala H, Hoppu K. Nasal sumatriptan is effective in treatment of migraine attacks in children: a randomized trial. Neurology. 2004;62:883–887
  34. Moerman DE. Cultural variations in the placebo effect: ulcers, anxiety, and blood pressure. Med Anthropol Q. 2000;14:51–72
  35. Winner P, Rothner AD, Wooten JD, Webster C, Ames M. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study. Headache. 2006;46:212–222
  36. Evers S, Rahmann A, Kraemer C, Kurlemann G, Debus O, Husstedt IW, et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology. 2006;67:497–499
  37. Ahonen K, Hamalainen ML, Eerola M, Hoppu K. A randomized trial of rizatriptan in migraine attacks in children. Neurology. 2006;67:1135–1140
  38. Emanuel EJ, Miller FG. The ethics of placebo-controlled trials: a middle ground. N Engl J Med. 2001;345:915–919
  39. Berlin JA, Santanna J, Schmid CH, Szczech LA, Feldman HI. Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Stat Med. 2002;21:371–387
  40. Freedman B, Glass KC, Weijer C. Placebo orthodoxy in clinical research (II: ethical, legal, and regulatory myths). J Law Med Ethics. 1996;24:252–259
  41. Ellenberg SS, Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments (Part 2: practical issues and specific cases). Ann Intern Med. 2000;133:464–470
  42. Lewis JA, Jonsson B, Kreutz G, Sampaio C, van Zwieten-Boot B. Placebo-controlled trials and the Declaration of Helsinki. Lancet. 2002;359:1337–1340
  43. Miller FG, Wendler D, Wilfond B. When do the federal regulations allow placebo-controlled trials in children?. J Pediatr. 2003;142:102–107
  44. de Craen AJ, Tijssen JG, de Gans J, Kleijnen J. Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos. J Neurol. 2000;247:183–188
  45. Macedo A, Sampaio C. Influence of placebo effect on planning and analysis of clinical trials. Rev Port Cardiol. 2001;20:313–319[in Portuguese]
  46. Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. JAMA. 1994;271:1609–1614

 No reprints are available from the authors.

PII: S0022-3476(07)00883-9

doi: 10.1016/j.jpeds.2007.09.024

The Journal of Pediatrics
Volume 152, Issue 4 , Pages 527-533.e1 , April 2008

Article Tools

* Image Usage & Resolution